Literature DB >> 26335954

Inflammation and its genesis in cystic fibrosis.

David P Nichols1,2,3, James F Chmiel4.   

Abstract

The host inflammatory response in cystic fibrosis (CF) lung disease has long been recognized as a central pathological feature and an important therapeutic target. Indeed, many believe that bronchiectasis results largely from the oxidative and proteolytic damage comprised within an exuberant airway inflammatory response that is dominated by neutrophils. In this review, we address the longstanding argument of whether or not the inflammatory response is directly attributable to impairment of the cystic fibrosis transmembrane conductance regulator or only secondary to airway obstruction and chronic bacterial infection and challenge the importance of this distinction in the context of therapy. We also review the centrality of neutrophils in CF lung pathophysiology and highlight more recent data that suggest the importance of other cell types and signaling beyond NF-κB activation. We discuss how protease and redox imbalance are critical factors in CF airway inflammation and end by reviewing some of the more promising therapeutic approaches now under development.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-inflammatory; cystic fibrosis; elastase; inflammation; neutrophil

Mesh:

Substances:

Year:  2015        PMID: 26335954     DOI: 10.1002/ppul.23242

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  61 in total

Review 1.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

Review 2.  Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.

Authors:  Thiago Inácio Teixeira do Carmo; Victor Emanuel Miranda Soares; Jonatha Wruck; Fernanda Dos Anjos; Débora Tavares de Resende E Silva; Sarah Franco Vieira de Oliveira Maciel; Margarete Dulce Bagatini
Journal:  Inflamm Res       Date:  2021-04-27       Impact factor: 4.575

Review 3.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

4.  SuFEx-enabled, agnostic discovery of covalent inhibitors of human neutrophil elastase.

Authors:  Qinheng Zheng; Jordan L Woehl; Seiya Kitamura; Diogo Santos-Martins; Christopher J Smedley; Gencheng Li; Stefano Forli; John E Moses; Dennis W Wolan; K Barry Sharpless
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

5.  Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators.

Authors:  Becca A Flitter; Kelli L Hvorecny; Emiko Ono; Taylor Eddens; Jun Yang; Daniel H Kwak; Christopher D Bahl; Thomas H Hampton; Christophe Morisseau; Bruce D Hammock; Xinyu Liu; Janet S Lee; Jay K Kolls; Bruce D Levy; Dean R Madden; Jennifer M Bomberger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-15       Impact factor: 11.205

Review 6.  Mucosal-associated invariant T cells: new players in CF lung disease?

Authors:  Nidhi Anil
Journal:  Inflamm Res       Date:  2019-06-14       Impact factor: 4.575

Review 7.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

8.  Human epididymis protein 4 (HE4) protects against cystic pulmonary fibrosis associated-inflammation through inhibition of NF-κB and MAPK singnaling.

Authors:  Jinli Wang; Hongyang Zhao; Fenfen Xu; Piaopiao Zhang; Yuan Zheng; Nan Jia
Journal:  Genes Genomics       Date:  2019-06-04       Impact factor: 1.839

9.  Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.

Authors:  Deepika Polineni; Hong Dang; Paul J Gallins; Lisa C Jones; Rhonda G Pace; Jaclyn R Stonebraker; Leah A Commander; Jeanne E Krenicky; Yi-Hui Zhou; Harriet Corvol; Garry R Cutting; Mitchell L Drumm; Lisa J Strug; Michael P Boyle; Peter R Durie; James F Chmiel; Fei Zou; Fred A Wright; Wanda K O'Neal; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

Review 10.  Cystic Fibrosis: Microbiology and Host Response.

Authors:  Edith T Zemanick; Lucas R Hoffman
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.